Weekly Investment Analysts’ Ratings Changes for ACADIA Pharmaceuticals (ACAD)

Several analysts have recently updated their ratings and price targets for ACADIA Pharmaceuticals (NASDAQ: ACAD):

• 9/29/2025 – ACADIA Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $34.00 to $33.00. They now have an “overweight” rating on the stock.
• 9/25/2025 – ACADIA Pharmaceuticals was given a new $29.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
• 9/24/2025 – ACADIA Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $30.00 to $28.00. They now have a “buy” rating on the stock.
• 9/11/2025 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 9/11/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at TD Cowen from $35.00 to $39.00. They now have a “buy” rating on the stock.
• 9/9/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at UBS Group AG from $36.00 to $39.00. They now have a “buy” rating on the stock.
• 9/5/2025 – ACADIA Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 8/16/2025 – ACADIA Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 8/8/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at UBS Group AG from $32.00 to $36.00. They now have a “buy” rating on the stock.
• 8/7/2025 – ACADIA Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 8/7/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a “sell” rating on the stock.
• 8/7/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $40.00. They now have an “outperform” rating on the stock.
• 8/7/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Mizuho from $23.00 to $24.00. They now have a “neutral” rating on the stock.
• 8/7/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at JMP Securities from $37.00 to $38.00. They now have a “market outperform” rating on the stock.

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 22,000 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $25.18, for a total transaction of $553,960.00. Following the completion of the sale, the executive vice president directly owned 40,130 shares in the company, valued at $1,010,473.40. This represents a 35.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total value of $41,568.00. Following the sale, the director directly owned 25,382 shares of the company’s stock, valued at approximately $659,424.36. This trade represents a 5.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,098 shares of company stock worth $678,256 over the last ninety days. Insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.